Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy.

The reactivity of 33 choroidal and ciliary body melanomas with monoclonal antibody Ki-67, which recognizes a proliferation associated nuclear antigen, has been assessed and compared with clinicopathologic parameters. In 23 cases, 8 Gy irradiation was given 2 days before enucleation. Nonirradiated melanomas had a significantly higher proliferation rate as defined by staining with monoclonal antibody Ki-67 as compared with irradiated tumors (P = 0.007). Similarly, a strong relationship was found between pre-enucleation irradiation and low mitotic activity (P = 0.001). There was no significant correlation between the presence of Ki-67-positive nuclei and histologic classification, largest tumor diameter, localization of the tumor, age, sex, scleral invasion, pigmentation, and lymphocytic infiltration. The relevance of Ki-67 immunohistochemistry for the assessment of the life prognosis of patients with uveal melanoma has to be studied prospectively.

[1]  F. Bosman,et al.  Studies with anti-bromodeoxyuridine antibodies: II. Simultaneous immunocytochemical detection of antigen expression and DNA synthesis by in vivo labeling of mouse intestinal mucosa. , 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  W. Göhde,et al.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle , 1975, Radiation and environmental biophysics.

[3]  J. Shields,et al.  The effect of pre-enucleation radiotherapy on mitotic activity of choroidal and ciliary body melanomas. , 1987, Ophthalmology.

[4]  T. Murakami,et al.  The cell cycle associated change of the Ki‐67 reactive nuclear antigen expression , 1987, Journal of cellular physiology.

[5]  H Stein,et al.  Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. , 1986, Journal of clinical pathology.

[6]  H. Stein,et al.  Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. , 1986, Journal of immunological methods.

[7]  P. Kleihues,et al.  Growth rate of human pituitary adenomas. , 1987, Journal of neurosurgery.

[8]  N. Shepherd,et al.  Ki‐67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations , 1988, The Journal of pathology.

[9]  T. Lister,et al.  The prognostic value of Ki67 immunostaining in non‐Hodgkin's lymphoma , 1988, The Journal of pathology.

[10]  H. Stein,et al.  New approach to assessing lung tumours in man. , 1986, Journal of clinical pathology.

[11]  D. Mason,et al.  Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67. , 1988, British Journal of Cancer.

[12]  D. Jewell,et al.  Immunohistologic demonstration of abnormal colonic crypt cell kinetics in ulcerative colitis. , 1985, Human pathology.

[13]  H. V. van Peperzeel,et al.  Choroidal Melanoma: Enucleation or Observation? A New Approach , 1980 .

[14]  J. Gerdes,et al.  Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation‐associated antibody Ki‐67 and propidium iodide: analysis by flow cytometry , 1987, Cell and tissue kinetics.

[15]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[16]  D. Char,et al.  DNA content abnormalities and prognosis in uveal melanoma. , 1986, Archives of ophthalmology.

[17]  S. Silverberg,et al.  Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumors of the uterus. , 1976, Human pathology.

[18]  N. Lemoine,et al.  Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables , 1987, The Journal of pathology.

[19]  P. Hall,et al.  In situ demonstration of renal tubular regeneration using the monoclonal antibody Ki67. , 1988, Nephron.

[20]  van der Kwast Th,et al.  Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. , 1987 .

[21]  H. Stein,et al.  Expression of a cell-cycle-associated nuclear antigen (Ki-67) in cutaneous lymphoid infiltrates. , 1986, The American Journal of dermatopathology.

[22]  D. Char.  DNA cell cycle studies in uveal melanoma. , 1988, Transactions of the American Ophthalmological Society.

[23]  K. Helweg-larsen,et al.  MITOTIC ACTIVITY AND DELAY IN FIXATION OF TUMOUR TISSUE , 1979, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[24]  M. Karnovsky,et al.  CYTOCHEMICAL DEMONSTRATION OF PEROXIDASE ACTIVITY WITH 3-AMINO-9-ETHYLCARBAZOLE , 1965, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  R. Warnke,et al.  Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody. , 1987, Human pathology.

[26]  W. Stolz,et al.  Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. , 1989, The American journal of pathology.

[27]  G. Wilson,et al.  The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry. , 1985, Cytometry.

[28]  K. Lennert,et al.  Growth fractions in malignant non‐Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki‐67 , 1984, Hematological oncology.

[29]  D. Jones,et al.  A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. , 1987, British Journal of Cancer.

[30]  B. Shapiro,et al.  Flow cytometry of uveal melanomas. , 1986, Cancer biochemistry biophysics.

[31]  W. Franklin,et al.  Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast , 1987, Cancer.

[32]  T. H. van der Kwast,et al.  Immunocytochemical staining of proliferating cells in fine needle aspiration smears of primary and metastatic breast tumours. , 1988, British Journal of Cancer.

[33]  K. Sasaki,et al.  Relationship between labeling indices of KI‐67 and brdurd in human malignant tumors , 1988, Cancer.

[34]  J. Gerdes.  An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery , 1985, International journal of cancer.

[35]  J. Meyer,et al.  Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. , 1989, The American journal of pathology.

[36]  T. H. van der Kwast,et al.  Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. , 1989, The Journal of urology.

[37]  R. Camplejohn,et al.  Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. , 1988, British Journal of Cancer.